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277 pp. $19.89p53, arguably themost heavily scrutinized
gene in biomedical research, is best
known as a tumor suppressor protein
that prevents animals and humans from
developing a wide array of tumors. It
does this largely by serving as a transcrip-
tion factor that is activated by myriad
stress signaling pathways (such as DNA
damage) to mediate an equally broad
range of cellular outcomes that may
facilitate protection from cancer (such as
programmed cell death). At the time of
writing this Book Review, typing p53 into
PubMed elicited an impressive 76,729
hits. This means that writing a book
on this gene, the history behind it, and
why it is so important and obsessively
analyzed and re-analyzed by literally
hundreds of scientists worldwide is a
truly daunting assignment. Happily, Sue
Armstrong, an accomplished health and
science writer, has stepped up to the
task admirably.
Having been steeped in p53 research
for the past 25 years, I worried before-
hand that the book might be unbalanced,
filled with factual errors, or worst of all,
deadly boring. Thankfully, my fears were
unfounded. Armstrong’s book is genu-
inely engrossing on many levels, and the
story is very well told. It has considerable
depth, yet sufficient clarity to be able to
reach a wide audience. She covers most
of the key discoveries—how the protein
was found to be a tumor suppressor,
how it works in cells, the invaluable knowl-
edge gained from p53 mouse models,
how the protein is regulated (or de-regu-
lated in some cases), and what happens
to cells when it is activated. She does
not flood the reader with endless cold
facts; rather, you learn about them as
part of the process of scientific discovery,
including the set-backs, the trials, and
the ultimate triumphs. Since p53 has
become relevant to so many different
fields, Armstrong deftly explains the
basics of human genetics, the conceptual
basis of tumor suppression, how DNAcan be damaged and repaired, how cells
die, and many other processes. In my
opinion, however, it is really the human
angle that makes this book so interesting.
Her human touch works on three levels.
First, the story is told from the perspec-
tive of a special subset of cancer patients,
those with Li Fraumeni syndrome (LFS).
The syndrome is named after the epide-
miologists who identified this rare heredi-
tary condition that predisposes patients
to early, frequent, and in many cases,
multiple forms of cancer. LFS was later
shown to occur very often as a result
of germline mutations in the p53 gene.
LFS patients are born with one good and
one mutated p53 gene in all their cells,
and their tumors have usually lost
or mutated the good gene. Armstrong
starts by describing with both eloquence
and compassion a patient living under
the shadow of LFS, who, like several of
her relatives, was diagnosed with cancer
at a young age. LFS patients are strong
motivators for researchers to keep slavingCellaway at trying to figure out how p53
works and what we can do to harness
our knowledge for cancer diagnosis and
treatment. The still broader motivation is
that, while these Li-Fraumeni patients
are fortunately very rare, p53 mutations
are in fact very commonly detected in
several forms of sporadic (non-inherited)
human patients’ tumors. Indeed, p53
is perhaps the most frequently mutated
of all cancer-related genes. And in tumors
with the wild-type (normal) form of the
protein, p53 can be throttled by other
means such as overexpression of Mdm2,
its negative regulator, or viral proteins
that disable its protective effects.
The second human aspect of this
book is the way Armstrong relays how
the discoveries were made about p53.
To gain first-hand knowledge, she trav-
eled widely to personally interview many
people (including myself) who contributed
at some point in their career to the body
of knowledge about p53. She describes
these conversations with considerable
charm, capturing the physical attributes
and personalities of her interviewees, as
well as their individual accounts of how
they arrived at their respective scientific
findings. These are woven into a coherent
narrative that paints a vivid picture of the
discoveries made about this gene and
why it is so important. In doing so, she
reveals many of the human aspects
of the scientific process—how theories
often need to be changed to fit the facts
and how scientists collaborate and
compete with each other (sometimes
simultaneously) to make key discoveries.
Armstrong also interviewed people who
did not work directly on p53, but whose
work was necessary to set the stage for
later discoveries about p53 itself. Particu-
larly well done is her recounting of
how p53 was originally thought to be
an oncogene but was subsequently
shown to be a tumor suppressor. It is
now believed that some of the more
common mutant forms of p53 found
in tumors do indeed contribute to malig-
nancy, whereas the wild-type form is
protective from the very same cancer.
The third human aspect of the story
reads like a movie script, where Big
Bad Industry (Big Tobacco in this case)
tries to cover up findings that will bring
it down—in this case, the mutation
spectrum of p53 was used to support162, July 30, 2015 ª2015 Elsevier Inc. 463
the link between cigarettes and lung
cancer. This saga has the requisite
good guys (researchers who realized
that the p53 mutations in smokers’ lung
tumors were caused by tobacco carcino-
gens) pitted against the bad guys
(dishonest scientists and even journal
editors who were financially beholden to
Big Tobacco) who tried to discount p53
as the ‘‘smoking gun’’ that revealed
the dangers of tobacco smoking. And
indeed, like all satisfying movies, the
good guys win out in the end.
So in all, this is a highly readable, well-
written, and crafted book that covers
nearly all the major discoveries about464 Cell 162, July 30, 2015 ª2015 Elsevier Inthis fascinating protein. I do have a couple
of quibbles, though. There is little if any
mention about the discovery of the ARF
protein as the molecular explanation
for how some oncogenes activate p53
as a protective mechanism from un-
scheduled hyper-proliferative signals.
The book also lacks significant mention
of the very likely crucial roles played by
p53 in preventing cells from acquiring
the metabolic changes seen in cancer
cells. On a personal level, although it
was admittedly flattering to see my own
story well told, Armstrong misnamed the
post-doc in my lab, Jill Bargonetti, who
showed that p53 binds specifically toc.DNA (she called her Jo Bargonetti) and
also mentioned mistakenly that Jill’s
work was published in another journal
rather than here in this one. Since it is
not realistic to try to unearth all such
inaccuracies, one cannot know if we
were an isolated case or not. That said,
even if some facts were a bit off-kilter,
the overall story of p53 as relayed
by Sue Armstrong is correct and very
engaging. I think this book will not only
be greatly appreciated by p53 and other
cancer researchers but will also be
enjoyed by the far greater arena of lay
readers. I will be recommending it to my
book group this summer.Carol Prives1,*
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